Menu
Recruiting NCT06285357

The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.

No phase Interventional HPV Infection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: EGCG + folic acid + B12.
Who it may be relevant to
Registry conditions: HPV Infection. Basic parameters: 25 years — 65 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.

Overview

The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.

Interventions

  • Dietary supplement EGCG + folic acid + B12
    EGCG + folic acid + B12

Primary outcome measures

  • HPV DNA test negativity [Time frame: 8 months of treatment]

Eligibility criteria

Inclusion criteria

  • HR-HPV DNA test positivity

Exclusion criteria

  • No HSIL

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Italy · 1 center
  • Azienda Ospedaliero-Universitaria di Modena — Modena

Identifiers

NCT: NCT06285357 · EPISTOP_22

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗